Harbour BioMed's Partner Spruce Biosciences Separates CRHX-101 Program into Adrenyx Biosciences, Advancing Development of Harbour BioMed-Originated Antibody through a Standalone Company

Logo

CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, Nov. 17, 2026 /PRNewswire/ -- Harbour BioMed (the "Company"; HKEX: 02142), a global biopharmaceutical company committed to the discovery and development of novel antibody therapeutics in immunology, oncology and other areas, today announced that its partner Spruce Biosciences (Nasdaq: SPRB) ("Spruce") has separated its CRHX-101 (formerly SPR-202 and HBM9013) program into Adrenyx Biosciences ("Adrenyx").

Logo

Recommended for you